Alnylam Shares Slip 7% Despite Swing To Q4 Profit

Core Viewpoint - Alnylam Pharmaceuticals reported a profitable fourth quarter, yet its stock price declined significantly despite the positive earnings report [1][2]. Financial Performance - The company achieved a net income of $111.5 million, or $0.82 per share, compared to a loss of $83.8 million, or $0.65 per share, in the same quarter last year [2]. - Adjusted earnings per share rose to $1.25 from $0.06, indicating a substantial improvement in profitability [2]. - Total revenues nearly doubled to $1.10 billion from $593.17 million, showcasing strong growth [2]. - Net product revenues increased to $994.7 million from $450.8 million, reflecting robust sales performance [2]. Stock Performance - Alnylam shares fell by 6.54 percent, closing at $300.70, down from a previous close of $321.75 [1]. - The stock traded within a range of $298.00 to $315.51 during the session on Nasdaq, with a trading volume of 552,594 shares, below the average volume of 1,494,936 [1]. Future Projections - For the year 2026, the company projects total net product revenues to be in the range of $4.9 billion to $5.3 billion, indicating optimistic growth expectations [3].